Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Lancet Oncol
; 18(12): 1590-1599, 2017 12.
Article
in En
| MEDLINE
| ID: mdl-29074098
Full text:
1
Database:
MEDLINE
Main subject:
Protein-Tyrosine Kinases
/
Gene Rearrangement
/
Proto-Oncogene Proteins
/
Receptor Protein-Tyrosine Kinases
/
Carcinoma, Non-Small-Cell Lung
/
Lactams, Macrocyclic
/
Lung Neoplasms
Type of study:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Humans
/
Middle aged
Language:
En
Year:
2017
Type:
Article